Sign In
Buy FDMT
$10.18
+0.110 (+1.09%)
At Close: Jul 31, 2026
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
07:56pm, Monday, 11'th Aug 2025
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.63 per share a year ago.
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
08:00am, Monday, 11'th Aug 2025
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
08:00am, Wednesday, 06'th Aug 2025
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
These 3 health tech stocks spiked 37% in a day; Time to buy?
05:56am, Monday, 04'th Aug 2025
While the broader stock market suffered steep losses on Friday amid trade policy shifts and troubling economic data, select health technology equities stood out.
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
04:05pm, Thursday, 31'st Jul 2025
EMERYVILLE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
08:00am, Thursday, 24'th Jul 2025
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 11'th Jul 2025
EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
04:05pm, Wednesday, 02'nd Jul 2025
EMERYVILLE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4DMT to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 28'th May 2025
EMERYVILLE, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 16'th May 2025
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
06:50pm, Thursday, 08'th May 2025
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.66 per share a year ago.
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
04:05pm, Thursday, 08'th May 2025
EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4DMT to Participate in Upcoming Investor Conferences
08:00am, Monday, 05'th May 2025
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted th
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
08:00am, Thursday, 01'st May 2025
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 11'th Apr 2025
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
